Aerobic Exercise-induced Effect on Endothelial Function in Patients With Ischaemic Heart Disease
NCT06788275, Not applicable, Recruiting, Instituto de Investigación Sanitaria y Biomédica de Alicante
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Aerobic Exercise-induced Effect on Endothelial Function in Patients With Ischaemic Heart Disease | ClinicalTrials.gov |
| NCT number | NCT06788275 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 132 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Instituto de Investigación Sanitaria y Biomédica de Alicante | ClinicalTrials.gov |
| Conditions | Percutaneous Coronary Intervention (PCI), Acute Myocardial Infarction, Angina (Stable), Unstable Angina Pectoris, Cardiorespiratory Fitness, Ischaemic Heart Diseases | ClinicalTrials.gov |
| Interventions | Aerobic exercise (MIT), Aerobic exercise (Short HIIT), Aerobic exercise (Long HIIT) | ClinicalTrials.gov |
| First posted | 2025-01-23 | ClinicalTrials.gov |
| Last updated | 2026-02-27 | ClinicalTrials.gov |
Registered outcomes 24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change from baseline in endothelial function at 7 weeks | 7 weeks | Endothelial function (i.e., endothelial-dependent dilation) will be assessed by brachial FMD. | ClinicalTrials.gov |
| Primary | Change from baseline in endothelial function at 14 weeks | 14 weeks | Endothelial function (i.e., endothelial-dependent dilation) will be assessed by brachial FMD. | ClinicalTrials.gov |
| Primary | Change from baseline in endothelial-independent dilation at 7 weeks | 7 weeks | Brachial NMD will be used to measure endothelial-independent dilation. | ClinicalTrials.gov |
| Primary | Change from baseline in endothelial-independent dilation at 14 weeks | 14 weeks | Brachial NMD will be used to measure endothelial-independent dilation. | ClinicalTrials.gov |
| Primary | Change from baseline in peak cardiopulmonary parameters at 7 weeks | 7 weeks | Participants will perform a symptom-limited CPET on a cycle ergometer. | ClinicalTrials.gov |
| Primary | Change from baseline in peak cardiopulmonary parameters at 14 weeks | 14 weeks | Participants will perform a symptom-limited CPET on a cycle ergometer. | ClinicalTrials.gov |
| Primary | Change from baseline in aerobic efficiency at 7 weeks | 7 weeks | Efficiency-related variables will be measured during the CPET. | ClinicalTrials.gov |
| Primary | Change from baseline in aerobic efficiency at 14 weeks | 14 weeks | Efficiency-related variables will be measured during the CPET. | ClinicalTrials.gov |
| Primary | Change from baseline in resting serum BDNF concentration at 7 weeks | 7 weeks | Blood samples will be obtained through an indwelling catheter placed in the antecubital vein before the CPET. | ClinicalTrials.gov |
| Primary | Change from baseline in resting serum BDNF concentration at 14 weeks | 14 weeks | Blood samples will be obtained through an indwelling catheter placed in the antecubital vein before the CPET. | ClinicalTrials.gov |
| Primary | Change from baseline in exercise-induced effect on serum BDNF at 7 weeks | 7 weeks | Blood samples will be obtained through an indwelling catheter placed in the antecubital vein before and after the CPET. | ClinicalTrials.gov |
| Primary | Change from baseline in exercise-induced effect on serum BDNF at 14 weeks | 14 weeks | Blood samples will be obtained through an indwelling catheter placed in the antecubital vein before and after the CPET. | ClinicalTrials.gov |
| Secondary | Change from baseline in pulmonary function at 7 and 14 weeks | 7 and 14 weeks | Pulmonary function will be measured by spirometry | ClinicalTrials.gov |
| Secondary | Change from baseline in resting cardiopulmonary parameters at 7 and 14 weeks | 7 and 14 weeks | Patients will be asked to rest for 5 min before stating the CPET. | ClinicalTrials.gov |
| Secondary | Change from baseline in cardiopulmonary parameters at first and second ventilatory thresholds at 7 and 14 weeks | 7 and 14 weeks | First and second ventilatory threshold during the CPET will be analysed blindly using the ventilatory equivalents method. | ClinicalTrials.gov |
| Secondary | Change from baseline in cardiopulmonary variables measured during the recovery at 7 and 14 weeks. | 7 and 14 weeks | Cardiopulmonary variables will be measured during the 3-min recovery period of the CPET. | ClinicalTrials.gov |
| Secondary | Change from baseline in MacNew domains at 7 and 14 weeks | 7 and 14 weeks | The MacNew heart disease health-related quality of life instrument will be used as a disease-specific quality of life questionnaire. The MacNew consists of 27 items that fall into three domains (a 13-item physical limitations domain scale, a 14-item emotional function domain scale, and a 13-item social function domain scale). Scoring of the MacNew is straightforward. The maximum possible score in any domain is 7 (high quality of life) and the minimum is 1 (poor quality of life). | ClinicalTrials.gov |
| Secondary | Change from baseline in body composition at 7 and 14 weeks | 7 and 14 weeks | Bioimpedance assessment will be conducted in fasting state. | ClinicalTrials.gov |
| Secondary | Change from baseline in resting heart rate variability (HRV) at 7 and 14 weeks | 7 and 14 weeks | HRV will be measured after an overnight fasting period at the same time of day | ClinicalTrials.gov |
| Secondary | Change from baseline in echocardiographic variables at 7 and 14 weeks | 7 and 14 weeks | A resting echocardiographic assessment will be performed before starting the CPET. The echocardiographic variables measured will be left ventricular end-diastolic diameter, septal and posterior wall thickness, left atrium dimension and volume, left ventricular ejection fraction (four-chamber and biplane Simpson's method, tricuspid annular plane systolic excursion, S' wave velocity, peak E and A wave velocities (in sinus rhythm), lateral and medial e' velocities, peak tricuspid regurgitation gradient, and velocity and gradient across the aortic valve. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 37576344 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Corsi Block-Tapping Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)